Chart-Typ:
Zeitraum:
| CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen |
| CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen |
| CG Oncology Inc.: CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates | Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated... ► Artikel lesen |
| Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen |
| Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate | KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN, Mass.... ► Artikel lesen |
| Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting | WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen |
| QIAGEN N.V.: QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026 | Highlights solutions addressing key oncology research needs across automated sample preparation, single-cell analysis, genomic profiling and data analysis QIAsymphony Connect will serve... ► Artikel lesen |
| QIAGEN N.V.: QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel | QIAstat-Dx BCID GPF Plus AMR Panel detects gram-positive bacteria, fungi and key antimicrobial resistance markers from positive blood cultures and colonies CE-IVDR-certified panel identifies... ► Artikel lesen |
| BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANNEXIN PHARMACEUTICALS AB finden Sie auf Wallstreet Online.